<DOC>
	<DOCNO>NCT01254877</DOCNO>
	<brief_summary>The propose randomized clinical trial investigate novel pharmacotherapy hazardous drinking , HIV-infected men woman , use 5-HT3 antagonist ondansetron . The investigator predict participant treat active dos ondansetron reduce drink show well HIV treatment participation progress compare participant treat placebo . This study provide important new safety efficacy result drink HIV outcome follow alcohol pharmacotherapy HIV-infected person .</brief_summary>
	<brief_title>Ondansetron , Alcohol Use , Alcohol-Related Symptoms In HIV+ Persons</brief_title>
	<detailed_description>Hazardous drink particularly harmful HIV-infected person . It impair immune system , accelerate HIV disease progression , slow initiation ART decrease adherence . Thus , development effective alcohol treatment clinical population particularly important . The investigator propose investigate effectiveness ondansetron pharmacotherapy treatment hazardous alcohol use alcohol abuse/dependence among HIV-infected patient . Ondansetron , 5-HT3 antagonist , study several reason : 1 ) evidence effectiveness person want cut-down reduce drink abstinent medication initiation ; 2 ) moderate-to-strong effect among early onset problem drinker , characteristic represent clinic patient ; 3 ) mild side-effect profile , make ideal pharmacotherapy candidate patient often receive multiple medication significant side-effects ; 4 ) primary indication treatment nausea , common side-effect antiretroviral ( ARV ) medication . The propose study placebo-controlled , randomized clinical trial ondansetron treatment hazardous drinking alcohol use disorder among HIV-infected patient recruit Baltimore/Washington area . Participants genotyped functional polymorphism serotonin transporter gene . They randomize one three treatment group : placebo , low dose ondansetron ( 0.2 mg bid ) moderate dose ondansetron ( 0.8 mg bid ) . All subject undergo 16 week pharmacotherapy combination medication management , follow 3 6 month medication end .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Subjects least 18 year old HIVinfected All subject actively drink hazardous level ( 1 ) AUDIT score = &gt; 4 woman = &gt; 8 men , 2 ) = &gt; 2 binge drink episodes/month , 3 ) &gt; 7 drinks/week woman &gt; 14 drinks/week men ) LFTs &gt; 5 X normal Magnesium potassium &gt; 3 X normal Qtc = &gt; .460 family history LQT Inability read comprehend English Actively psychotic severe mental health symptom would prevent appropriate participation Current enrollment alcoholism treatment program Pregnancy ; Ondansetron currently category B drug . While animal data identify harmful effect mother fetus , adequate human control trial recommend routine use population</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV</keyword>
</DOC>